Pulmonary Hypertension

HomePatientsLung Disease Week at the ATS2016 ▶ Pulmonary Hypertension
Pulmonary Hypertension Week

Pulmonary Hypertension Week

Welcome Message

I would like to welcome you for visiting with us during Pulmonary Hypertension Week for the American Thoracic Society. It is with pleasure that we use this week to introduce pulmonary hypertension to a wide-reaching audience and explain our current knowledge and future perspectives of this disease. The ATS has been instrumental in supporting ongoing research, through the Pulmonary Circulation Assembly and other Assemblies as well, by promoting advancements in our understanding of cellular and molecular mechanisms of pulmonary vascular function, gas exchange and right heart dysfunction while encouraging new and innovative clinical trials, drug development, diagnostic and therapeutic interventions in pulmonary vascular disease. The Pulmonary Hypertension Association is another great resource with abundant information, educational programs, support groups and resources for patients, families and medical practitioners regarding pulmonary hypertension.

Pulmonary hypertension represents a chronic, progressive condition characterized by high blood pressure in the pulmonary circulation. Patients often experience tiredness, shortness of breath, chest pain, fainting, and swelling of the legs and abdomen. This condition often complicates many common diseases such as congestive heart failure, autoimmune diseases, sickle cell anemia, chronic obstructive pulmonary disease or blood clots in the pulmonary circulation. The presence of pulmonary hypertension dramatically increases the risk of death in these conditions. Our improved understanding and recognition of pulmonary hypertension has uncovered the impressive burden of this disease on our healthcare system. The most recent estimates indicate that pulmonary hypertension is responsible for 260,000 hospital visits and over 15,000 deaths per year. We hope that Pulmonary Hypertension Week for the American Thoracic Society will help increase the public recognition of this devastating disease which will continue to advance ongoing research and drug development.

 

Samya Nasr, MD

Samya Nasr, MD
Professor of Pediatrics
University of Michigan Health Systems
Member, Council of Chapter Representatives
American Thoracic Society

Debbie Drell

Debbie Drell
Senior Director, Volunteer Services
Pulmonary Hypertension Association
Chair-elect, ATS Public Advisory Roundtable

 

ATS Pulmonary Hypertension PARTNER

PHA

 

The mission of the Pulmonary Hypertension Association (PHA) is to extend and improve the lives of those affected by Pulmonary Hypertension.

The Pulmonary Hypertension Association is a young organization, changing the history of an illness. From simple beginnings — four women around a kitchen table in Florida in 1990 — Pulmonary Hypertension Association has evolved in size and complexity. Membership now includes over 16,000 patients and family members as well as two medical membership sections, one for physicians and researchers, the other for non-physician clinicians. The synergy created from the partnership of these constituencies has resulted in a community of hope and effective change.